Application of indolepropionic acid in treatment of clostridium difficile infection
Indolepropionic acid addresses the dysbiosis problem that existing antibiotic therapies have failed to solve in the treatment of Clostridium difficile infection by improving gut microbiota dysbiosis, restoring the intestinal mechanical and mucus barriers, and reducing the expression of inflammatory factors, thus achieving effective treatment of CDI.
Patent Information
- Application Number
- CN202410981390.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-12
AI Technical Summary
While existing antibiotic therapies are effective in treating Clostridium difficile infection (CDI), they fail to address the underlying gut microbiota dysbiosis and may lead to drug resistance and disruption of the gut microbiota, necessitating the search for new treatment methods.
Indolepropionic acid is used as an AhR agonist to treat susceptible and antibiotic-resistant Clostridium difficile infections. It improves gut microbiota dysbiosis, reduces cytotoxicity, restores the intestinal mechanical and mucus barriers, reduces the expression of inflammatory factors, and restores gut health.
Indolepropionic acid significantly improves CDI symptoms, reduces weight loss, restores intestinal structure and function, reduces inflammatory response, has no obvious side effects, and is superior to other AhR agonists.
Smart Images

Figure CN118924742A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to application of indolepropionic acid in treating Clostridium difficile infection. Background Art
[0002] Clostridium difficile (CD) is a Gram-positive anaerobic bacillus, including non-toxigenic strains and toxigenic strains. Non-toxigenic strains do not produce toxins and are non-pathogenic. Clostridium difficile infection (CDI) is an infectious disease caused by excessive proliferation and release of toxins by toxin-producing Clostridium difficile after the normal intestinal flora is destroyed. The clinical manifestations can range from mild self-healing diarrhea to severe pseudomembranous colitis, sepsis syndrome, toxic megacolon and even intestinal perforation. The main risk factors for CDI include: (1) irrational use of antibiotics: the most common antibiotics include broad-spectrum cephalosporins, fluoroquinolones and clindamycin; (2) age > 65 years: elderly patients have reduced intestinal immune function and are prone to intestinal microecology disorders, which makes CD easy to multiply; (3) use of proton pump inhibitors (PPI); (4) previous history of CDI; (5) immunosuppression, including factors such as malignant tumors and organ transplantation.
[0003] Metronidazole and vancomycin are currently the first-line drugs for the treatment of CDI in my country. Metronidazole has a strong antibacterial effect on anaerobic bacteria, is low-priced, and has rapid and accurate efficacy, but metronidazole is active against most anaerobic organisms and may significantly damage the intestinal microbiota. Vancomycin has a narrow antibacterial spectrum and has a strong bactericidal effect on Gram-positive cocci and Gram-positive bacilli. It is particularly effective against CD and is the first choice for the treatment of Clostridium difficile-associated diarrhea, but it is expensive. Fidaxomicin is the third drug for the treatment of CDI-associated diarrhea. Compared with vancomycin, fidaxomicin can reduce the recurrence rate of CDI, probably because fidaxomicin has little effect on normal intestinal flora. Fidaxomicin can only be administered orally and is suitable for patients with recurrent or severe CDI.
[0004] Although current antibiotic therapy is relatively effective in treating active CDI, it does not address the dysbiosis underlying the disease. More attention needs to be paid to strengthening C. difficile infection at the clinical level to avoid blindly using broad-spectrum antimicrobial drugs, thereby reducing the incidence and spread of drug-resistant C. difficile infection. These limitations highlight the necessity and urgency of finding other innovative and accessible therapies for CDI.
[0005] Chinese patent CN109661236A discloses a bacterial composition that can be used to treat dysbiosis, for example, in humans. The patent discloses that indole and indole derivatives have been implicated in host physiology, for example, indole and indole-3-aldehyde are agonists of the aryl hydrocarbon receptor (AhR), which can induce IL-22 expression and increase Th-17 activity. In addition, the patent discloses that AhR agonists can improve the effects of Clostridium difficile infection in a mouse model. However, there are many types of AhR agonists, and the patent does not study whether all AhR agonists can improve the effects of Clostridium difficile infection in a mouse model.
[0006] In view of this, in order to solve the deficiencies of the prior art, the present invention provides the use of indolepropionic acid in treating Clostridium difficile infection. Indolepropionic acid can significantly improve the symptoms of CDI without obvious side effects. Summary of the invention
[0007] The purpose of the present invention is to provide the use of indolepropionic acid in treating Clostridium difficile infection. The indolepropionic acid has a mild effect, has no influence on antibiotic resistance, and can be used sustainably.
[0008] To achieve the above-mentioned purpose of the invention, the technical solution of the present invention is as follows:
[0009] The present invention provides application of indolepropionic acid in preparing medicine for treating Clostridium difficile infectious diseases and complications thereof.
[0010] Preferably, the Clostridium difficile includes strains with reduced sensitivity and strains of Clostridium difficile that are resistant to antibiotics.
[0011] More preferably, the antibiotic is selected from at least one of ampicillin, cephalosporin, lincomycin, clindamycin, erythromycin, tetracycline, vancomycin and metronidazole.
[0012] Preferably, the symptoms of Clostridium difficile infection disease include watery diarrhea, abdominal pain, fever, nausea and vomiting, weakness, loss of appetite, colon inflammation, damaged intestinal mucus barrier and damaged intestinal mechanical barrier.
[0013] Further preferably, the symptoms of Clostridium difficile infection disease include watery diarrhea, loss of appetite, colon inflammation, damaged intestinal mucus barrier and damaged intestinal mechanical barrier.
[0014] More preferably, the symptoms of Clostridium difficile infection disease include watery diarrhea, colon inflammation, damaged intestinal mucus barrier and damaged intestinal mechanical barrier.
[0015] Preferably, the complications of the Clostridium difficile infectious disease include severe dehydration, abdominal distension, hypoproteinemia with peripheral edema, circulatory shock, toxic megacolon, colon perforation, intestinal paralysis, renal failure, systemic inflammatory response syndrome, sepsis and death.
[0016] Further preferably, the complications of the Clostridium difficile infectious disease include severe dehydration, abdominal distension, hypoproteinemia with peripheral edema, circulatory shock and toxic megacolon.
[0017] Even more preferably, the complications of the Clostridium difficile infectious disease include severe dehydration, abdominal distension, and toxic megacolon.
[0018] Preferably, the medicament comprises an effective amount of indolepropionic acid.
[0019] Further preferably, the drug is in the form of at least one selected from pills, capsules, granules, oral liquids, powders, tablets, lozenges, and lozenges, and a suitable drug carrier in the art may be selected for different dosage forms.
[0020] The pharmaceutical carrier used can be solid, liquid or gas. Examples of solid carriers include lactose, kaolin, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate and stearic acid. Examples of liquid carriers include syrup, peanut oil, olive oil and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
[0021] When preparing the composition for oral dosage form, any convenient pharmaceutical medium can be used. For example, water, ethanol, oil, alcohol, flavoring agent, preservative, coloring agent, etc. can be used to form oral liquid preparations, such as suspensions and solutions; while carriers, such as starch, sugars, microcrystalline cellulose, diluents, granulating agents, emulsifiers, lubricants, binders, disintegrants can be used to form oral solid preparations, such as powders, capsules and tablets. Tablets and capsules are the preferred oral dosage units using solid pharmaceutical carriers due to their ease of administration. Tablets can be coated using standard aqueous or non-aqueous techniques.
[0022] The pharmaceutical composition suitable for parenteral administration of the present invention can be prepared as an aqueous solution or suspension of the active compound. Suitable surfactants such as hydroxypropylcellulose can be included. Dispersions can also be prepared in glycerol, liquid polyethylene glycol and oil mixtures thereof. In addition, preservatives can be added to prevent the harmful growth of microorganisms.
[0023] The pharmaceutical preparation of the present invention may be in a form suitable for topical use, such as an aerosol, cream, ointment, lotion, powder or the like.
[0024] The pharmaceutical preparation of the present invention can be in a form suitable for rectal administration, wherein the carrier is a solid. Preferably, the mixture is made into a unit dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories can be prepared by first forming a composition containing a softened or melted carrier, followed by cooling and shaping in a mold.
[0025] In addition to the above-mentioned carrier components, the above-mentioned pharmaceutical preparations may include (if applicable) one or more additional carrier components, such as diluents, buffers, flavoring agents, binders, surfactants, thickeners, lubricants, preservatives (including antioxidants), etc. In addition, other excipients, such as colorants and flavoring agents such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc., may be added.
[0026] More preferably, the drug is an oral drug preparation.
[0027] The beneficial effects of the present invention are:
[0028] Compared with other types of AhR agonists, such as indole-3-carboxaldehyde, 3-indolemethanol, and indole-3-pyruvic acid, indolepropionic acid is more effective in treating Clostridium difficile infection and can more effectively reduce the cytotoxicity of Clostridium difficile strains. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 Oral administration of indolepropionic acid can effectively improve weight loss and HE staining results in CDI.
[0030] Figure 2 The results showed that indolepropionic acid did not affect the growth of Clostridium difficile in vitro, but reduced the cytotoxicity of the bacterial supernatant in a concentration-dependent manner.
[0031] Figure 3 Oral administration of indolepropionic acid can improve the immunofluorescence results of the mechanical barrier represented by ZO-1 and Claudin-1 in CDI mice.
[0032] Figure 4 Oral administration of indolepropionic acid can improve the AB-PAS staining results in CDI mice.
[0033] Figure 5 The results showed that oral administration of indolepropionic acid could improve the mRNA expression levels of inflammatory indicators tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), interleukin 6 (IL-6) and interleukin 10 (IL-10) in CDI mice.
[0034] Figure 6 The results showed that oral administration of indolepropionic acid can effectively upregulate the expression level of pregnane X receptor (PXR) in the colon tissue of CDI mice.
[0035] Among them, Blank represents blank control group, CDI represents Clostridium difficile infection group, CDI+IPA represents indolepropionic acid group, CDI+I3C represents indole-3-carboxaldehyde group, CDI+3-IC represents 3-indolemethanol group, and CDI+IAA represents indole-3-pyruvic acid group. DETAILED DESCRIPTION
[0036] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is only an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the invention of the present invention based on the disclosed content, and they should also fall within the scope of the present application.
[0037] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.
[0038] Indolepropionic acid (IPA): Sigma-Aldrich, Catalog No. 220027;
[0039] Indole-3-carboxaldehyde (I3C): Sigma-Aldrich, Catalog No. 129445;
[0040] 3-Indolecarbinol (3-IC): Sigma-Aldrich, Catalog No. I7256;
[0041] Indole-3-pyruvic acid (IAA): Sigma-Aldrich, Catalog No. I7017.
[0042] Example 1: Construction and sampling of CDI mouse model
[0043] 1. Test samples
[0044] Sterile physiological saline was used to prepare suspensions of indolepropionic acid, indole-3-carboxaldehyde, 3-indolemethanol and indole-3-pyruvic acid, respectively.
[0045] 2. Experimental Animals
[0046] 36 BABL / C mice, SPF grade, weighing 21-23g, 6-7 weeks old, half male and half female. Provided by Liaoning Changsheng Biotechnology Co., Ltd., Laboratory Animal Quality Certificate No.: NO.210726230101278285, Laboratory Animal Production License No.: SCXK(Liao)2020-0001. Feeding conditions: temperature 20-26℃, humidity 40-70%, day and night light and dark alternation time 12h / 12h, mice free food and water. After one week of adaptive feeding of mice, the experiment was carried out.
[0047] 3. Modeling
[0048] Six days before oral gavage with Clostridium difficile, mice were allowed to drink a mixture containing multiple antibiotics, in which the concentrations of the antibiotics were: kanamycin 0.8 mg / mL, gentamicin 0.07 mg / mL, vancomycin 0.09 mg / mL, metronidazole 0.43 mg / mL, and polymyxin 0.1135 mg / mL. The mixture was prepared with purified and disinfected drinking water. To ensure the efficacy, new antibiotic mixtures were prepared for mice to drink every day. On the third to last day, the antibiotic mixture was replaced with purified and disinfected drinking water. 24 hours later, 1 mg / kg of clindamycin was given to the mice by intraperitoneal injection to further induce imbalance in their intestinal flora. 24 hours later (day 0 of the experiment), the mice were orally gavaged with 1×10 7 The bacterial liquid of CFU Clostridium difficile, the strain of Clostridium difficile is the standard strain VPI10463.
[0049] 4. Grouped medication
[0050] The medication was divided into groups according to Table 1.
[0051] Table 1. Grouping and dosage design
[0052]
[0053]
[0054] Before C. difficile infection, mice in the indolepropionic acid group, indole-3-formaldehyde group, 3-indolemethanol group, and indole-3-pyruvic acid group were gavaged with the suspension 5 days in advance and continued until the end of modeling. Correspondingly, mice in the blank control group and C. difficile infection group were gavaged with 200uL sterile saline.
[0055] In order to monitor the condition of the mice, the weight of the mice was measured at 9 am every day (make sure it is at a fixed time period) and recorded. At the same time, the food intake, water intake, activity level and mental state of the mice were recorded. During the examination, the mice were observed for diarrhea or wet tails, whether their hair maintained a good luster, whether they lost hair, and their overall body shape. All these observations will be recorded in detail. On the third day of infection, all animals were fasted for 24 hours, and then euthanized to obtain their colon, liver, spleen tissues and intestinal contents for subsequent experiments.
[0056] The results showed that indolepropionic acid could significantly improve the weight loss of CDI mice ( Figure 1 a) in the figure.
[0057] Example 2: HE staining and colon pathology scoring
[0058] 1. HE staining
[0059] The paraffin-embedded tissue sections were dewaxed in xylene twice, each time for 15 minutes, and then immersed in 100%, 95%, 80%, and 70% alcohol for 2 minutes each to hydrate, rinsed in distilled water for 2 minutes, stained in hematoxylin for 3 minutes, and then rinsed in tap water for 2 minutes; differentiated in 1% hydrochloric acid alcohol for 30 seconds, rinsed in tap water for 2 minutes, blued in ammonia water for 30 seconds, and rinsed in tap water for 2 minutes; stained in eosin for 1-3 minutes, rinsed in distilled water for 1 minute, and then immersed in 70%, 80%, 95%, and 100% alcohol for 1 minute each to dehydrate, and finally transparentized in xylene twice, each for 5 minutes, and observed under a microscope after sealing.
[0060] 2. Colon pathology scoring
[0061] The pathological score of mouse colon tissue was evaluated based on the following characteristics: (1) the degree of tissue infiltration of inflammatory cells, mainly neutrophils; (2) hemorrhagic congestion and edema of the mucosa; (3) epithelial cell damage, including vacuolization, apoptosis, attenuation or necrosis of the villus tip, and pseudomembrane formation (pseudomembrane is mainly composed of bacteria, neutrophils, fibrinoid substances, desquamated epithelial cells and cell debris). Each parameter was assigned a score from 0 to 3 to reflect the severity of the abnormality (mild, moderate, severe). The total score is the sum of all component scores.
[0062] The results showed that the epithelial structure of the colon mucosa in the CDI group was destroyed, partially shed, and ulcers were formed. At the same time, inflammatory cells infiltrated, goblet cells decreased, colon glands disappeared, crypts were deformed or even shed, and pseudomembranes even appeared in the intestinal cavity. Indolepropionic acid treatment significantly improved the pathological changes of the colon tissue of mice (histopathological score P = 0.029, Figure 1b) in the above, and significantly better than indole-3-carboxaldehyde, 3-indole methanol and indole-3-pyruvic acid. Based on the above data, further research is conducted on indole propionic acid, which has the best therapeutic effect.
[0063] Example 3: Effect of indolepropionic acid on Clostridium difficile strains in vitro
[0064] In order to analyze the effect of indolepropionic acid on the growth of Clostridium difficile VPI10463, indolepropionic acid was added to 5 mL of Clostridium difficile culture medium. The concentrations of indolepropionic acid in the culture medium were 0.1 μM, 1 μM, and 10 μM, respectively. The OD of the bacterial solution was detected. 600 The supernatant of the bacterial suspension of Clostridium difficile grown in medium containing different concentrations of indolepropionic acid was further extracted, filtered and sterilized, and added to intestinal epithelial cells Caco-2 cells. The effect of different concentrations of indolepropionic acid on the toxin production level of Clostridium difficile VPI10463 was analyzed by calcein-AM / PI double staining and LDH detection.
[0065] The results showed that compared with brain heart infusion broth without indolepropionic acid, the medium with different concentrations of indolepropionic acid had no significant difference in the growth of Clostridium difficile strains ( Figure 2 a); In Caco-2 cells, LDH test data and double staining test data suggest that the virulence of C. difficile decreases with the increase of indolepropionic acid concentration (in the range of 0.1-10 μM) ( Figure 2 b, c) in the above.
[0066] Example 4: Immunofluorescence detection of intestinal mechanical barrier integrity (ZO-1 and Claudin-1)
[0067] Paraffin-embedded tissue sections were dewaxed in xylene twice for 15 minutes each time, and then immersed in 100%, 95%, 80%, and 70% alcohol for 2 minutes each for hydration. After rinsing in distilled water for 2 minutes, they were microwaved in citric acid buffer for 10 minutes for antigen repair, and washed three times with PBS after cooling; blocked in 5% normal serum for 1 hour, added with primary antibody and incubated at 4°C overnight, washed three times with PBS the next day, and then added with fluorescently labeled secondary antibody for incubation for 1 hour (protected from light), and washed three times with PBS; after drying the sections, DAPI was added to stain the nucleus in the dark for 5 minutes, and washed three times with PBS; anti-fluorescence quenching sealing agent was added, and the sections were observed under a fluorescence microscope after coverslipping, and the detected fluorescence intensity was semi-quantitatively analyzed using Image Plo Plus software.
[0068] The results showed that compared with the blank control group, the expression of ZO-1 and Claudin-1 in the colon tissue of CDI mice was significantly decreased. Indolepropionic acid could partially restore the expression of ZO-1 and Claudin-1 in the colon tissue, and there was a significant statistical difference between the two groups ( Figure 3a, b, c, d).
[0069] Example 5: AB_PAS staining to detect intestinal mucus barrier integrity
[0070] Paraffin-embedded tissue sections were dewaxed in xylene twice, each time for 15 minutes, and then immersed in 100%, 95%, 80%, and 70% alcohol for 2 minutes each for hydration, rinsed in distilled water for 2 minutes, immersed in 1% acetic acid for 3 minutes, and then stained in 1% Alcian blue (AB) solution for 30 minutes, followed by rinsing in 1% acetic acid for 2 minutes and in distilled water for 2 minutes; then, immersed in 0.5% potassium ferrocyanide solution for 1 minute and rinsed in distilled water for 2 minutes; then oxidized in 1% periodic acid solution for 5 minutes and rinsed in distilled water for 2 minutes; finally, stained in Schiff's reagent (PAS) for 15 minutes, rinsed in tap water for 5 minutes, dehydrated and transparent, and sealed and observed under a microscope.
[0071] The results showed that compared with the blank control group, the blue staining in the CDI group samples was significantly reduced, suggesting that the mucus content was significantly reduced, especially the number of mucus-rich goblet cells was significantly reduced and no longer full. Oral administration of indolepropionic acid can significantly improve the destruction of the mucus barrier caused by infection ( Figure 4 a, b) in the figure.
[0072] Example 6: RT-PCR detection of changes in inflammatory indicators in colon tissue
[0073] 1. RNA extraction
[0074] Add 1 mL of Trizol (RNAiso Plus) to the tissue, let it stand for 5 minutes, mix with a pipette, and collect in an Eppendorf centrifuge tube. Add 0.2 mL of chloroform (one-fifth of the volume of Trizol), cover tightly and shake thoroughly for 15 seconds until emulsified. Let stand at room temperature for 5 minutes (preset the centrifuge to 4°C and 12,000g at this time). Centrifuge at 4°C and 12,000g for 15 minutes, take the upper transparent liquid, add 0.4 mL of isopropanol (equal volume to the supernatant), mix slowly up and down 5 times, and let stand at room temperature for 10 minutes. Centrifuge at 4°C and 12,000g for 10 minutes, and discard the supernatant after the precipitate is seen at the bottom.
[0075] Gently add 1 mL of 75% ethanol (prepared with DEPC water), flick the RNA precipitate to rinse, centrifuge at 4°C and 7500g for 5 minutes, and aspirate the supernatant as thoroughly as possible to prevent the loss of RNA precipitate. Invert the EP tube to dry the water droplets on the tube wall, dissolve the dried RNA with 30μ of DEPC water, measure the OD260 / 280 value with a spectrophotometer, prepare the working concentration (1μg / μL), and detect the RNA integrity with 1% agarose gel electrophoresis, and store at -80°C for use.
[0076] 2. Reverse transcription reaction
[0077] Reverse transcription uses the TAKARA kit, and 10 μL system reverses 1000 ng of RNA. Taking the reversal of 1 μg RNA and 20 μL system as an example, take reagents 1, 2, and 3 in the reverse transcription kit. Measure the concentration of each RNA and calculate the amount required for 1 μg RNA. Take a common eight-link PCR tube and add the following systems respectively:
[0078] -5*Primescript RT Enzyme MIX(4μL)
[0079] -Total RNA
[0080] -RNase Free ddH2O (make up to 20μL)
[0081] Reverse transcription was performed on a common PCR instrument at 37°C for 15 min, 85°C for 30 s, and stored at 4°C.
[0082] 3. Real-time fluorescence-PCR
[0083] Take a 1.5mL EP tube and prepare a mixture of 2*TB Green, primers and ddH2O.
[0084] 10μL system:
[0085] -2*TB Green (5μL)
[0086] - Primers (0.3 μL each for forward and reverse)
[0087] -ddH2O (make up to 6μL)
[0088] The mixed solution was dispensed into a real-time PCR plate, 6 μL per well, and the plate was operated on ice. Then 4 μL of the corresponding diluted template was added to each well to start the PCR reaction.
[0089] 4. Primer sequence
[0090] Table 2. QPCR primer sequences
[0091] Gene Forward Primer Reverse primer Mus-βactin CATTGCTGACAGGATGCAGAAGG TGCTGGAAGGTGGACAGTGAGG Mus-IL-1β TGGACCTTCCAGGATGAGGACA GTTCATCTCGGAGCCTGTAGTG Mus-TNFα GGTGCCTATGTCTCAGCCTCTT GCCATAGAACTGATGAGAGGGAG Mus-IL10 CGGGAAGACAATAACTGCACCC CGGTTAGCAGTATGTTGTCCAGC Mus-IL6 TACCACTTCACAAGTCGGAGGC CTGCAAGTGCATCATCGTTGTTC
[0092] The results showed that oral administration of indolepropionic acid could significantly reduce the expression of TNF-α, IL-1β, and IL-6 caused by CDI, and at the same time significantly restore the decreased expression of IL-10 anti-inflammatory factor caused by CDI ( Figure 5 ).
[0093] Example 7: Immunohistochemical detection of PXR receptor changes in colon tissue
[0094] Paraffin-embedded tissue sections were dewaxed in xylene twice, 15 minutes each time, and then immersed in 100%, 95%, 80%, and 70% alcohol for 2 minutes each to hydrate. After rinsing in distilled water for 2 minutes, they were microwaved in citric acid buffer for 10 minutes for antigen repair, cooled and washed 3 times with PBS; blocked in 5% normal serum for 1 hour, added with primary antibody and incubated at 4°C overnight, washed 3 times with PBS the next day, added with biotin-labeled secondary antibody, and then incubated with enzyme-labeled streptavidin complex. Finally, substrate was added for color development, counterstained, sealed and examined under a microscope, and semi-quantitative analysis was performed using Image Plo Plus software.
[0095] The results showed that compared with the blank control group, the overall expression of PXR in the colon of mice infected with Clostridium difficile was significantly reduced, while IPA treatment restored the expression of PXR ( Figure 6 a, b) in the figure.
[0096] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. The application of indolepropionic acid in the preparation of drugs for treating Clostridium difficile infectious diseases and their complications.
2. The use according to claim 1, It is characterized in that The Clostridium difficile includes strains with reduced sensitivity and strains of Clostridium difficile that are resistant to antibiotics.
3. The use according to claim 2, It is characterized in that The antibiotic is selected from at least one of ampicillin, cephalosporin, lincomycin, clindamycin, erythromycin, tetracycline, vancomycin and metronidazole.
4. The use according to claim 1, It is characterized in that Symptoms of the Clostridium difficile infection include watery diarrhea, abdominal pain, fever, nausea and vomiting, weakness, loss of appetite, colon inflammation, impaired intestinal mucus barrier, and damaged intestinal mechanical barrier.
5. The use according to claim 4, It is characterized in that Symptoms of the Clostridium difficile infection disease include watery diarrhea, loss of appetite, colon inflammation, damaged intestinal mucus barrier, and damaged intestinal mechanical barrier.
6. The use according to claim 5, It is characterized in that Symptoms of the Clostridium difficile infection disease include watery diarrhea, colon inflammation, impaired intestinal mucus barrier, and damaged intestinal mechanical barrier.
7. The use according to claim 1, It is characterized in that Complications of Clostridium difficile infectious disease include severe dehydration, abdominal distention, hypoproteinemia with peripheral edema, circulatory shock, toxic megacolon, colonic perforation, intestinal paralysis, renal failure, systemic inflammatory response syndrome, sepsis, and death.
8. The use according to claim 7, It is characterized in that Complications of Clostridium difficile infection include severe dehydration, abdominal distention, hypoproteinemia with peripheral edema, circulatory shock, and toxic megacolon.
9. The use according to claim 8, It is characterized in that Complications of C. difficile infection include severe dehydration, abdominal distension, and toxic megacolon.
10. The use according to claim 1, It is characterized in that The medicine is an oral pharmaceutical preparation.
Citation Information
Cited By
Application of indole-3-propionic acid in preparation of medicine for preventing or treating hematogenous infection
CN119679788A
Use of indole-3-propionic acid for the preparation of a medicament for the prevention or treatment of blood-borne infections
CN119679788B
